Psoriatic Arthritis Treatment Market Revenue to Cross USD 13.74 Billion by 2026: AMR

According to the report, the global psoriatic arthritis treatment industry was pegged at $7.86 billion in 2018, and is expected to reach $13.74 billion by 2026, growing at a CAGR of 7.2% from 2019 to 2026. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

Key Takeaways:

The Psoriatic Arthritis Treatment market is experiencing significant growth and is expected to continue expanding in the coming years.

The market is driven by factors such as the increasing prevalence of psoriatic arthritis, advancements in treatment options, and growing awareness among patients and healthcare professionals.

The primary treatment options for psoriatic arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic therapies.

Biologic therapies, such as tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and Janus kinase (JAK) inhibitors, have gained considerable traction in recent years due to their effectiveness in managing symptoms and slowing disease progression.

The market is witnessing the emergence of novel treatment approaches, including targeted therapies and small molecule inhibitors, which hold promise for improved outcomes in psoriatic arthritis patients.

Request Sample Copy of the Report:

https://www.alliedmarketresearch.com/request-sample/6316

Market Drivers:

Increasing Prevalence: The rising prevalence of psoriatic arthritis globally is a significant driver for the market. The condition affects a considerable number of individuals, creating a substantial patient population in need of effective treatment options.

Advancements in Treatment Options: The development of new and improved treatment options for psoriatic arthritis, including biologic therapies and targeted therapies, has significantly contributed to market growth. These advancements offer enhanced efficacy, improved symptom management, and better disease control.

Growing Awareness: Increased awareness among patients and healthcare professionals about psoriatic arthritis has led to early diagnosis and proactive treatment. As awareness grows, the demand for effective treatments also increases, driving market growth.

Favorable Reimbursement Policies: Favorable reimbursement policies and insurance coverage for psoriatic arthritis treatments have made them more accessible and affordable for patients. This factor plays a crucial role in driving market growth by ensuring broader patient access to treatment options.

Market Segmentation:

Treatment Type:

• • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Biologic Therapies
  • Targeted Therapies
  • Others

Route of Administration:

• • Oral
  • Injectable
  • Topical

Distribution Channel:

• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Geography:

• • North America (United States, Canada)
  • Europe (United Kingdom, Germany, France, Italy, Spain, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • Middle East & Africa (GCC Countries, South Africa, Rest of Middle East & Africa)

End-User:

• • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings

Request for Customization – 

https://www.alliedmarketresearch.com/request-for-customization/6316

Regional Growth Dynamics:

The global psoriatic arthritis treatment market across North America held the largest share in 2018, contributing for more than half of the market, owing to presence of key players in the region. Moreover, rise in prevalence of psoriatic arthritis disease, surge in demand for psoriatic arthritis treatment drugs, presence of advanced healthcare facilities coupled with trained medical professionals, and surge in number of R&D centers significantly contribute toward the growth of the North America market. However, the Asia-Pacific segment is expected to register the fastest CAGR of 9.1% during the forecast period, owing to high population base, surge in awareness about psoriatic arthritis treatment products, and increase in prevalence of psoriasis & psoriatic arthritis disease in various countries.

Competitive Landscape:

• AbbVie Inc.
• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Janssen Pharmaceutical Companies (Johnson & Johnson)
• Novartis AG
• Pfizer Inc.
• UCB S.A.
• Celgene Corporation (acquired by Bristol Myers Squibb)
• Merck & Co., Inc.

Recent developments:

• Approval of New Therapies: In recent years, several new therapies have been approved for the treatment of psoriatic arthritis. This includes the approval of interleukin inhibitors such as ixekizumab, secukinumab, and brodalumab, as well as Janus kinase (JAK) inhibitors like tofacitinib and upadacitinib. These approvals have expanded the treatment options available for psoriatic arthritis patients.
• Targeted Therapies: Targeted therapies that specifically inhibit certain molecules or pathways involved in psoriatic arthritis have shown promising results. For example, phosphodiesterase-4 (PDE4) inhibitors like apremilast have been approved for the treatment of psoriatic arthritis, providing an alternative treatment option.
• Biosimilars: The market has seen the introduction of biosimilar versions of existing biologic therapies used in psoriatic arthritis treatment. Biosimilars offer more affordable alternatives while maintaining similar efficacy and safety profiles. This trend has increased competition and improved patient access to these therapies.

Buy this Premium Research Report: 

https://www.alliedmarketresearch.com/purchase-enquiry/6316

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Browse more latest healthcare reports:

Sperm Bank Market by Donor Type (Known Donor and Anonymous Donor) and Service Type (Sperm Storage, Semen Analysis, and Genetic Consultation): Global Opportunity Analysis and Industry Forecast, 2020-2027

Cancer Diagnostics Market by Product (Consumables and Instruments), Application (Breast Cancer, Breast Cancer, Lung Cancer, Blood Cancer, Colorectal Cancer, Skin Cancer, Ovarian Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Cervical Cancer, and Others), and End Use (Hospitals & Clinics, Diagnostic Laboratories, Diagnostic Centers, and Research Institutes): Opportunity Analysis and Industry Forecast, 2021-2028

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com